Addressing Belantamab Mafodotin-Related Corneal Events in Myeloma is Key to Continuing Treatment

Ellie Leick
Published: Thursday, Dec 05, 2019
Rakesh Popat, MD, a professor in the Department of Medical Oncology, University of Washington School of Medicine, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance

Rakesh Popat, MD

Due to the potency of belantamab mafodotin (GSK2857916) in relapsed/ refractory multiple myeloma, as demonstrated in the DREAMM-1 trial, managing the associated corneal events is necessary in order to continue with treatment, explained Rakesh Popat, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication